Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 26 October, 2012 and appeared in  Cardiovascular HealthBlood Glucose ControlIssue 649

Reducing HbA1c Less than 1 Point Reduces Risk of Dying within 5 Years by 50 Percent

Patients who had suboptimal glycemic control and reduced their HbA1c value by slightly less than 1% were 50% less likely to die within 5 years than were patients whose HbA1c did not improve.... 
Advertisement

At 5 years, all-cause mortality was 15% among the group with no improvement in HbA1c and 10% in the group with improved HbA1c in an observational study of 12,359 patients with poorly controlled type 2 diabetes at baseline. The patients were selected from the Swedish National Diabetes Registry and their outcomes were verified by the Swedish Cause of Death and Hospital Registries. None of the patients had any cardiovascular or coronary heart disease at baseline.

After adjusting for baseline risk factors and treatment changes during the study period, patients whose HbA1c decreased were half as likely to develop cardiovascular or coronary heart disease as were those whose levels increased. They were also 33% less likely to experience fatal cardiovascular disease and 41% less likely to die from any cause than were those in the poorly controlled group. All of these differences were statistically significant.

Dr. Eeg-Olofsson of the University of Gothenburg, Sweden stated that, "Patients with poorly controlled blood glucose clearly benefit" from gaining and improving glycemic control. "We must make an effort to identify patients who don't respond to diabetes medications earlier."

For the study, Dr. Eeg-Olofssson separated the patients into two groups: Those whose HbA1c decreased by at least 0.1% over the 5 years (6,841) and those whose HbA1c remained stable or increased by at least 0.1% (5,518).

At baseline, the patients averaged 62 years old, with mean disease duration of 9 years. Their average baseline HbA1c was 7.8%, and their mean body mass index was 30 kg/m2. Their mean blood pressure was 140/78 mmHg; 62% were taking antihypertensives and 46% were on lipid-lowering drugs.

After 5 years, mean HbA1c was 7% in the improved-control group (-0.8%) and 8.4% in the poorly controlled group (+0.7%), she said.

By then, 12% of the well-controlled group and 20% of the poorly controlled group had developed coronary heart disease. Cardiovascular disease was present in 17% of those in the well-controlled group and 30% of the poorly controlled group. Both these findings were statistically significant.

Presented at the annual meeting of the European Association for the Study of Diabetes, Sept. 2012 (EASD).  

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 26 October, 2012 and appeared in  Cardiovascular HealthBlood Glucose ControlIssue 649

Past five issues: Diabetes Clinical Mastery Series Issue 137 | Issue 677 | Diabetes Clinical Mastery Series Issue 136 | Issue 676 | Diabetes Clinical Mastery Series Issue 135 |

2013 Most Popular Articles:

AACE Releases New Comprehensive Diabetes Management Algorithm
Posted April 25, 2013
AACE - New Diabetes Guidelines Based on Tailored Approach
Posted May 09, 2013
Discovery Raises Hope for Type 1 Diabetes Reversal
Posted May 03, 2013
AACE: Ralph A. DeFronzo, MD -- Diabetes Prevention Supports More Aggressive and Earlier Intervention
Posted May 09, 2013
Intermittent Fasting May Improve Diabetes and Reduce Cardiovascular Risk
Posted May 03, 2013
AACE – New Test Efficiently Detects Diabetic Neuropathy
Posted May 09, 2013
Diabetes Increases Cancer Risk by 20 Percent
Posted May 16, 2013
AACE: CAD Risk for Pre-Diabetes Similar to Diabetes
Posted May 09, 2013
Low-Glycemic Diet Seen to Reverse Diastolic Dysfunction of Diabetes
Posted May 03, 2013
New Pill in the Works for Type 1 Patients
Posted April 19, 2013

See more most popular…


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
 
Diabetes In Control Advertisers
 
Cast Your Vote
What test do you use to screen for prediabetes?

Navigate Diabetes In Control
Search Articles On Diabetes In Control